StandardX raises £10m led by Vsquared Ventures and East X Ventures
This article covers StandardX, a healthtech startup, which has raised £10m in a growth funding round to build an accelerator-based isotope refinery to increase domestic production of rare isotopes for cancer diagnostics, targeted therapies and research. The development aims to support hospitals, drug developers and research labs by strengthening isotope supply for diagnostics, therapies and clinical trials in the UK.
StandardX, a healthtech startup, has raised £10 million in a growth funding round to build an accelerator-based isotope refinery designed to increase domestic production of rare isotopes used in cancer diagnostics, targeted therapies and research. The funding will bankroll the company’s first industrial site in London, pilot production with a medical partner in 2027 and work towards industrial-scale output by 2029.
Why it matters
Medical isotopes are foundational to diagnostics and many cancer treatments, yet global production is concentrated in a few ageing facilities and is increasingly unable to meet demand. The shortage has practical consequences: NHS data shows only 69.6% of patients received treatment within 62 days of an urgent referral in May 2026, well below the 85% target, and clinical trials for some isotope-dependent therapies have been paused or delayed across the UK and Europe.
StandardX’s proposition addresses a supply-chain bottleneck that affects hospitals, drug developers and research labs. If successful, a distributed manufacturing model sited near centres of care and research could reduce transport delays, improve resilience and support next-generation radiopharmaceuticals that currently struggle to scale because of scarce inputs.
Inside the product
StandardX is developing what it calls an isotope refinery built around a proprietary accelerator system. Unlike narrow, isotope-specific infrastructure, each machine is intended to produce a wider portfolio of isotopes at commercial scale on a standard industrial footprint. The company plans to begin with medical isotopes for diagnostics and therapy, then extend to other industrial isotopes such as tritium, which is required for fusion energy.
Key timelines and capabilities disclosed by the company:
- Pilot production and first isotope deliveries to a medical research partner targeted for 2027.
- Industrial-scale production planned from 2029.
- Seed funding will support hiring, securing the first London industrial site and advancing the engineering and build of the first accelerator system.
StandardX was founded in 2025 by nuclear engineers Richard Pearson (CEO) and Ross Allen (CTO) and says its 15-strong team includes scientists and engineers with experience at SpaceX, The London Clinic, Oxford and Cambridge universities, Fermilab and the UK Atomic Energy Authority. The company has also signed agreements with fusion developers to supply tritium if fusion projects scale.
Who are the investors?
The raise was led by Vsquared Ventures and East X Ventures, with additional backing from firstminute capital, the UK Innovation and Science Seed Fund (managed by Future Planet Capital), Brevan Howard Macro Venture and Geometry.
The funding signals venture appetite for deep-tech manufacturing that intersects health and energy. Investors point to a combination of immediate market need in radiopharma and long-term optionality around fusion tritium, while noting the founders’ technical credentials and the team’s mix of academic and industrial experience.
In the announcement, Lise Rechsteiner, General Partner at Vsquared Ventures, said:
Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn’t kept pace. StandardX is building a fundamentally flexible production platform that can move with the science, from the isotopes medicine needs today to those that will define the next generation of cancer treatment. We believe it can become critical infrastructure for the next era of radiopharma and Richard and Ross have the rare technical expertise and ambition to build it. Being located in London puts StandardX at the heart of one of Europe’s leading ecosystems for cancer research and clinical trials.
In the announcement, Theodore Mollinger, General Partner at East X Ventures, said:
StandardX is tackling a supply problem that matters enormously today in medicine, while building a platform that could become critical infrastructure for fusion tomorrow. What makes the opportunity particularly compelling is the asymmetry: StandardX can build a valuable isotope business without relying on fusion timelines, but if fusion scales, tritium could become one of the defining industrial bottlenecks of the sector. With only a tiny global inventory today and substantial quantities ultimately required to fuel commercial fusion systems, we believe StandardX has the potential to play a critical role in securing that supply.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Richard Pearson, Co-founder & CEO at StandardX, said:
StandardX began with a problem: isotope supply limited by legacy infrastructure. This raise moves us from concept into engineering, physics into hardware, and conversations into delivery. Our immediate priority is our industrial site in London, where we will deploy our first isotope refinery system and work closely with clinicians and researchers to start building a reliable supply chain.
In the announcement, Ross Allen, Co-founder & CTO at StandardX, said:
Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn’t kept pace. StandardX is building a fundamentally flexible production platform that can move with the science, from the isotopes medicine needs today to those that will define the next generation of cancer treatment. We believe it can become critical infrastructure for the next era of radiopharma and Richard and Ross have the rare technical expertise and ambition to build it. Being located in London puts StandardX at the heart of one of Europe’s leading ecosystems for cancer research and clinical trials.
Funding will be used to grow the team, finalise engineering, secure premises in London and begin pilot manufacturing and distribution to clinical and research partners.
The bigger picture
The StandardX raise sits at the intersection of healthtech manufacturing and national resilience. For the NHS and UK research institutions, localised isotope production could reduce dependence on long, fragile supply chains and help keep clinical trials and novel therapies on schedule. For the broader European ecosystem, developing domestic capacity for key scientific inputs is a recurring policy and investment theme as countries look to reduce single-point failures in critical materials.
The company’s plan to pivot its platform toward tritium also ties the financing to wider energy ambitions: even if fusion timelines remain uncertain, securing potential future supply for fusion developers is an early example of private-market preparation for industrial-scale energy technologies. The deal highlights growing investor interest in hard-tech ventures that combine immediate clinical applications with long-term energy and industrial optionality in the UK and Europe.
They've invested in StandardX
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Vsquared Ventures( ) Munich, Germany  | ||||
 | ||||
 Firstminute Capital( ) firstminute capital is a seed-stage venture firm focused on investing in the UK,... London  | ||||
 | ||||
 Future Planet Capital( ) Future Planet Capital is an impact-led venture capital firm founded in the UK wi... London | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK